Advertisement

A Systematic Review of the Efficacy of Domperidone for the Treatment of Diabetic Gastroparesis

  • Aravind Sugumar
    Affiliations
    Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
    Search for articles by this author
  • Amanpal Singh
    Affiliations
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas
    Search for articles by this author
  • Pankaj Jay Pasricha
    Correspondence
    Address requests for reprints to: Pankaj J. Pasricha, MD, Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 300 Pasteur Drive, Alway Building, Room M211, Stanford, California 94305-5187. fax: (650) 723-5488.
    Affiliations
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California
    Search for articles by this author
      Background & Aims: Despite being widely used in more than 20 countries for the treatment of diabetic gastroparesis for several decades, domperidone is approved only on an investigational basis in the United States. However, because its use is increasing, it is important for gastroenterologists in this country to understand its effectiveness in this condition. The literature on this subject varies considerably with respect to the methods and outcome measures, making a meta-analysis unfeasible. Methods: Our objective was to systematically analyze studies of the efficacy of domperidone in diabetic gastroparesis, with a focus on their methodologic and scientific merit. Information from 28 trials (11 full articles and 17 abstracts) from 1981 to 2007 was analyzed. Results: The average study quality score was 8.3 out of a possible 15 and the total sample size equaled 1016. Overall, 64% of the studies showed significant efficacy of domperidone on the improvement of symptoms. Sixty percent of the studies showed an efficacy in gastric emptying and 67% of the studies proved the drug effective in reducing hospital admissions. Conclusions: Overall, our assessment is that there is level 3 evidence for the efficacy of domperidone in diabetic gastroparesis, leading to a grade C recommendation for its use in this condition. These results need to be interpreted very cautiously because of significant methodologic limitations of these studies, including the fact that most positive studies lacked a control arm. It is clear that larger and better-designed studies are needed to further validate the use of this drug in diabetic gastroparesis.

      Abbreviation used in this paper:

      FDA (Food and Drug Administration)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Loo F.D.
        • Palmer D.W.
        • Soergel K.H.
        • et al.
        Gastric emptying in patients with diabetes mellitus.
        Gastroenterology. 1984; 86: 485-494
        • Smith D.S.
        • Ferris C.D.
        Current concepts in diabetic gastroparesis.
        Drugs. 2003; 63: 1339-1358
        • Vittal H.
        • Farrugia G.
        • Gomez G.
        • et al.
        Mechanisms of disease: the pathological basis of gastroparesis—a review of experimental and clinical studies.
        Nat Clin Pract Gastroenterol Hepatol. 2007; 4: 336-346
        • Champion M.C.
        Management of idiopathic, diabetic and miscellaneous gastroparesis with cisapride.
        Scand J Gastroenterol Suppl. 1989; 165: 44-53
        • Dhir R.
        • Richter J.E.
        Erythromycin in the short- and long-term control of dyspepsia symptoms in patients with gastroparesis.
        J Clin Gastroenterol. 2004; 38: 237-242
        • Barone J.A.
        Domperidone: a peripherally acting dopamine2-receptor antagonist.
        Ann Pharmacother. 1999; 33: 429-440
        • Food and Drug Administration (Center for Drug Evaluation and Research)
        How to obtain domperidone.
        • Ahmad N.
        • Keith-Ferris J.
        • Gooden E.
        • et al.
        Making a case for domperidone in the treatment of gastrointestinal motility disorders.
        Curr Opin Pharmacol. 2006; 6: 571-576
        • Reddymasu S.C.
        • Soykan I.
        • McCallum R.W.
        Domperidone: review of pharmacology and clinical applications in gastroenterology.
        Am J Gastroenterol. 2007; 102: 2036-2045
        • Silvers D.
        • Kipnes M.
        • Broadstone V.
        • et al.
        Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial.
        Clin Ther. 1998; 20: 438-453
        • Franzese A.
        • Borrelli O.
        • Corrado G.
        • et al.
        Domperidone is more effective than cisapride in children with diabetic gastroparesis.
        Aliment Pharmacol Ther. 2002; 16: 951-957
        • Horowitz M.
        • Harding P.E.
        • Chatterton B.E.
        • et al.
        Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy.
        Dig Dis Sci. 1985; 30: 1-9
        • Patterson D.
        • Abell T.
        • Rothstein R.
        • et al.
        A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis.
        Am J Gastroenterol. 1999; 94: 1230-1234
        • Koch K.L.
        • Stern R.M.
        • Stewart W.R.
        • et al.
        Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment.
        Am J Gastroenterol. 1989; 84: 1069-1075
        • Braun A.P.
        Domperidone in the treatment of symptoms of delayed gastric emptying in diabetic patients.
        Adv Ther. 1989; 6: 51-62
        • Nagler J.
        • Miskovitz P.
        Clinical evaluation of domperidone in the treatment of chronic postprandial idiopathic upper gastrointestinal distress.
        Am J Gastroenterol. 1981; 76: 495-499
        • Heer M.
        • Müller-Duysing W.
        • Benes I.
        • et al.
        Diabetic gastroparesis: treatment with domperidone—a double-blind, placebo-controlled trial.
        Digestion. 1983; 27: 214-217
        • Watts G.F.
        • Armitage M.
        • Sinclair J.
        • et al.
        Treatment of diabetic gastroparesis with oral domperidone.
        Diabet Med. 1985; 2: 491-492
        • Soykan I.
        • Sarosiek I.
        • McCallum R.W.
        The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis.
        Am J Gastroenterol. 1997; 92: 976-980
        • Kozarek R.
        Domperidone for symptomatic management of diabetic gastroparesis in metoclopramide treatment failures.
        Adv Ther. 1990; 7: 61-68
        • Stern W.R.
        Summary of the 34th meeting of the Food and Drug Administration Gastrointestinal Drugs Advisory Committee.
        Am J Gastroenterol. 1989; 84: 1351-1355
        • Bingaman S.
        • Koch K.
        Long-term domperidone treatment for symptoms of gastroparesis in diabetic patients.
        Diabetes. 1997; 46: 1204
        • Miller M.
        • Patterson D.
        Natural history of diabetic gastroparesis treated with cisapride or domperidone.
        Am J Gastroenterol. 1991; 86 (1316): 1316
        • Patterson D.J.
        • Botoman V.A.
        • Kozarek R.A.
        • et al.
        Domperidone is effective long-term treatment for diabetic gastroparesis.
        Gastroenterology. 1991; 100: A137
        • Patterson D.
        • Koch K.
        • Abell T.
        • et al.
        A multicenter placebo-controlled study of domperidone in diabetic gastroparesis.
        Gastroenterology. 1993; 104: A564
        • Patterson D.
        • Meldrum N.
        • Kozarek R.M.
        Long-term efficacy of domperidone in patients with diabetes and symptoms of gastroparesis.
        Diabetes. 1997; 46: 490
        • Lehmann K.
        • Patterson D.J.
        Does combination prokinetic therapy benefit patients with refractory diabetic gastroparesis?.
        Gastroenterology. 1995; 108: A636
        • Koch K.L.
        • Bingaman S.
        • Stern R.M.
        Withdrawal study of domperidone vs placebo in diabetic patients: effect on upper gastrointestinal symptoms and gastric myoelectrical activity.
        Gastroenterology. 1995; 108: A630
        • Abell T.L.
        • Rashed H.
        • Cutts T.
        • et al.
        Autonomic function is a determinant of quality of life improvement in response to domperidone therapy.
        Diabetes. 1997; 46: 1445
        • Shifflett J.
        • McCallum R.W.
        Longterm efficacy, treatment outcome and quality of life in patients receiving chronic domperidone therapy for gastroparesis.
        Gastroenterology. 1995; 108: A35
        • Champion M.C.
        • Braaten J.
        • Gulenchyn K.
        Domperidone compared to cisapride in the management of gastroparesis.
        Am J Gastroenterol. 1991; 86: 1309
        • Dumitrascu D.L.
        • Weinbeck M.
        Domperidone versus metoclopramide in the treatment of diabetic gastroparesis.
        Am J Gastroeneterol. 2000; 95: 316-317
        • Champion M.C.
        • Gulenchyn K.
        • O'Leary T.
        • et al.
        Domperidone improves symptoms and solid phase gastric emptying in diabetic gastroparesis.
        Am J Gastroenterol. 1987; 82: 975
        • Schoenfeld P.
        • Cook D.
        • Hamilton F.
        • et al.
        An evidence-based approach to gastroenterology therapy.
        Gastroenterology. 1998; 114: 1318-1325
        • Jadad A.R.
        • Moore R.A.
        • Carroll D.
        • et al.
        Assessing the quality of reports of randomized clinical trials: is blinding necessary?.
        Control Clin Trials. 1996; 17: 1-12
        • Harris R.P.
        • Helfand M.
        • Woolf S.H.
        • et al.
        Current methods of the US Preventive Services Task Force: a review of the process.
        Am J Prev Med. 2001; 20: 21-35
        • Harvey J.A.
        • Cowan 3rd, J.H.
        • LoRusso A.P.
        Increase in mammographic breast density associated with the use of domperidone.
        Breast J. 2004; 10: 256-258
        • Wennbo H.
        • Tornell J.
        The role of prolactin and growth hormone in breast cancer.
        Oncogene. 2000; 19: 1072-1076